PL377495A1 - Stały lek do stosowania doustnego - Google Patents

Stały lek do stosowania doustnego

Info

Publication number
PL377495A1
PL377495A1 PL377495A PL37749503A PL377495A1 PL 377495 A1 PL377495 A1 PL 377495A1 PL 377495 A PL377495 A PL 377495A PL 37749503 A PL37749503 A PL 37749503A PL 377495 A1 PL377495 A1 PL 377495A1
Authority
PL
Poland
Prior art keywords
oral use
solid drug
drug
solid
oral
Prior art date
Application number
PL377495A
Other languages
English (en)
Other versions
PL220457B1 (pl
Inventor
Tsuyoshi Naganuma
Mitsuo Muramatsu
Original Assignee
Kissei Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32588229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL377495(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical Co., Ltd. filed Critical Kissei Pharmaceutical Co., Ltd.
Publication of PL377495A1 publication Critical patent/PL377495A1/pl
Publication of PL220457B1 publication Critical patent/PL220457B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL377495A 2002-12-16 2003-12-11 Kapsułka do leczenia dysurii PL220457B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002364238 2002-12-16

Publications (2)

Publication Number Publication Date
PL377495A1 true PL377495A1 (pl) 2006-02-06
PL220457B1 PL220457B1 (pl) 2015-10-30

Family

ID=32588229

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377495A PL220457B1 (pl) 2002-12-16 2003-12-11 Kapsułka do leczenia dysurii

Country Status (23)

Country Link
US (2) US20060018959A1 (pl)
EP (2) EP1574215B1 (pl)
JP (1) JP4633469B2 (pl)
KR (2) KR101077061B1 (pl)
CN (2) CN100339078C (pl)
AU (1) AU2003289320C1 (pl)
BR (1) BR0317349A (pl)
CA (1) CA2507002C (pl)
EA (1) EA008196B1 (pl)
ES (1) ES2544560T3 (pl)
HR (1) HRP20050544B1 (pl)
IL (1) IL169040A (pl)
IS (1) IS7929A (pl)
ME (2) MEP10808A (pl)
MX (1) MXPA05006513A (pl)
NO (1) NO20053467L (pl)
NZ (1) NZ540664A (pl)
PL (1) PL220457B1 (pl)
RS (1) RS58025B1 (pl)
TW (2) TWI325318B (pl)
UA (2) UA84694C2 (pl)
WO (1) WO2004054574A1 (pl)
ZA (1) ZA200504613B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5004215B2 (ja) * 2004-03-05 2012-08-22 キッセイ薬品工業株式会社 神経障害に伴う過活動膀胱の予防または治療用医薬組成物
KR100965205B1 (ko) * 2004-10-05 2010-06-24 깃세이 야쿠힌 고교 가부시키가이샤 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는치료제
WO2008106536A1 (en) * 2007-02-28 2008-09-04 Kissei Pharmaceuticals Co., Ltd. Use of silodosin in a once daily administration for treating benign prostatic hyperplasia
TW200900094A (en) * 2007-03-13 2009-01-01 Takeda Pharmaceutical Solid preparation
EP2585050B1 (de) 2010-06-28 2014-05-14 Ratiopharm GmbH Silodosin-cyclodextrin einschlussverbindungen
WO2012010669A2 (de) 2010-07-23 2012-01-26 Ratiopharm Gmbh Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
SI2474529T1 (sl) 2010-12-23 2014-12-31 Sandoz Ag Kristalne oblike aktivne farmacevtske učinkovine
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
US20140243383A1 (en) * 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
JP6031722B2 (ja) * 2011-08-31 2016-11-24 国立大学法人 千葉大学 女性の排尿障害の治療剤
EP2744498A4 (en) * 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
PL2872488T3 (pl) 2012-07-16 2019-01-31 Fibrogen, Inc. Postacie krystaliczne inhibitora hydroksylazy prolilowej
EP2979697A4 (en) 2013-03-26 2016-11-30 Kissei Pharmaceutical PREPARATION FOR ORAL ADMINISTRATION WITH MASKED BITTERNITY OF SILODOSINE
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
KR102206104B1 (ko) * 2014-04-03 2021-01-22 한미약품 주식회사 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
CN103933001A (zh) * 2014-05-09 2014-07-23 浙江华海药业股份有限公司 一种稳定的赛洛多辛口服固体药物组合物及其制备方法
CN105435233B (zh) * 2014-08-06 2018-05-01 江苏正大丰海制药有限公司 一种英加韦林的药物组合物
JP6366547B2 (ja) * 2015-08-03 2018-08-01 大原薬品工業株式会社 光安定性が向上した、プラミペキソール製剤包装体
CN108685867A (zh) * 2017-04-06 2018-10-23 昆明积大制药股份有限公司 一种赛洛多辛薄膜衣片及其制备方法
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
CN111437260A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 用于制备盐酸美金刚固态药物组合物的方法
JP7262005B2 (ja) * 2019-01-25 2023-04-21 日本ジェネリック株式会社 シロドシン含有固形組成物及びその製造法
CN114601826B (zh) * 2022-03-31 2024-06-04 乐泰药业有限公司 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060073A (en) 1963-03-02 1967-02-22 Benger Lab Ltd 2,2,2-trichlorethyl hydrogen succinate and salts
US4547498A (en) 1983-01-06 1985-10-15 Mylan Pharmaceuticals Inc. Pharmaceutical combination composition and associated method
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
HU200926B (en) * 1988-10-28 1990-09-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
EP0600675B1 (en) * 1992-12-02 1998-07-08 Kissei Pharmaceutical Co., Ltd. Indoline compounds for the treatment of dysuria
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
PT758244E (pt) 1994-05-06 2002-04-29 Pfizer Formas de dosagem libertacao controlada de azitromicina
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AU9095998A (en) * 1997-09-22 1999-04-12 Kissei Pharmaceutical Co. Ltd. Remedies for dysuria resulting from prostatic hypertrophy
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
US20010053780A1 (en) 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
JP4014068B2 (ja) * 1999-07-28 2007-11-28 芦森工業株式会社 エアバッグ装置
PE20011178A1 (es) * 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
EP1293206A4 (en) 2000-05-15 2005-09-21 Kissei Pharmaceutical LIQUID PREPARATION BASED ON WATER
ES2290562T3 (es) * 2001-01-26 2008-02-16 Schering Corporation Combinaciones del activador del receptor activado por el proliferador de los peroxisomas (ppar) fenofibrato con el inhibidor de la absorcion de esteroles ezetimiba para indicaciones vasculares.
JP2001288115A (ja) 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
KR20030076715A (ko) * 2001-03-01 2003-09-26 그레랑 파마수티컬 가부시키가이샤 페노피브라이트 함유 조성물
US6786714B2 (en) * 2001-04-12 2004-09-07 James W. Haskew Delivery system for liquid catalysts
GB0113843D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same

Also Published As

Publication number Publication date
EP1574215A4 (en) 2009-07-01
HK1085131A1 (en) 2006-08-18
PL220457B1 (pl) 2015-10-30
NO20053467L (no) 2005-07-15
IL169040A (en) 2013-04-30
WO2004054574A1 (ja) 2004-07-01
IS7929A (is) 2005-07-01
KR20050084316A (ko) 2005-08-26
TWI325318B (en) 2010-06-01
HRP20050544A2 (en) 2006-09-30
US20060018959A1 (en) 2006-01-26
JP4633469B2 (ja) 2011-02-16
EA008196B1 (ru) 2007-04-27
HK1107768A1 (en) 2008-04-18
UA85359C2 (ru) 2009-01-12
CN101069685B (zh) 2011-12-14
KR20100133024A (ko) 2010-12-20
CA2507002A1 (en) 2004-07-01
NZ540664A (en) 2007-09-28
EP1574215B1 (en) 2015-07-15
EP1574215A1 (en) 2005-09-14
ME00076B (me) 2011-02-10
MEP10808A (en) 2010-06-10
EP2402010A1 (en) 2012-01-04
KR101072909B1 (ko) 2011-10-17
ES2544560T3 (es) 2015-09-01
AU2003289320A1 (en) 2004-07-09
AU2003289320B2 (en) 2008-08-21
BR0317349A (pt) 2005-11-16
JPWO2004054574A1 (ja) 2006-04-20
US20120064154A1 (en) 2012-03-15
AU2003289320C1 (en) 2018-09-06
CN100339078C (zh) 2007-09-26
UA84694C2 (ru) 2008-11-25
EA200500985A1 (ru) 2005-12-29
MXPA05006513A (es) 2005-09-08
KR101077061B1 (ko) 2011-10-26
TW200418457A (en) 2004-10-01
RS58025B1 (sr) 2019-02-28
TW200944200A (en) 2009-11-01
CN1726028A (zh) 2006-01-25
RS20050470A (sr) 2007-09-21
ZA200504613B (en) 2006-08-30
CA2507002C (en) 2012-09-18
TWI382838B (zh) 2013-01-21
CN101069685A (zh) 2007-11-14
HRP20050544B1 (hr) 2017-12-01

Similar Documents

Publication Publication Date Title
GB2394894B (en) New use for pharmaceutical composition
AU2003244650A8 (en) Medicinal compounds
GB0225540D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0225535D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
GB0225030D0 (en) Medicinal compounds
PL377495A1 (pl) Stały lek do stosowania doustnego
GB0218625D0 (en) Pharmaceutical compounds
GB0210397D0 (en) Pharmaceutical formulations
EP1553925A4 (en) ORAL DOSAGE FORM WITH MODIFIED RELEASE
GB0215775D0 (en) Pharmaceutical compounds
GB2392093B (en) Pharmaceutical formulations
AU2003252683A8 (en) Composition for oral use
GB0206505D0 (en) Pharmaceutical combination
AP2004003087A0 (en) Oral dosage form for controlled drug release
PL373409A1 (pl) Kombinacja farmaceutyczna
GB0206708D0 (en) Pharmaceutical salts
GB0204683D0 (en) Pharmaceutical salts
GB0220451D0 (en) Pharmaceutical use
GB0224508D0 (en) Medicinal compounds
GB0225023D0 (en) Medicinal compounds
GB0209482D0 (en) Medicinal compounds
GB0215930D0 (en) Medicinal compounds
GB0220729D0 (en) Medicinal compounds